Full Press Release Details
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic.
IMMP
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
Key Takeaway: Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)